Compare Agnico Eagle Mines Ltd (AEM) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Amylx Pharmaceuticals Inc — how do they compare? Agnico Eagle Mines Ltd trades at $183.63 (market cap $91.28B), while Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B). The key difference: Agnico Eagle Mines Ltd is far larger — about 36.1× Amylx Pharmaceuticals Inc's market cap, and Agnico Eagle Mines Ltd pays a 1% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AEM | AMLX | |
|---|---|---|
Market Cap | $91.28B | $2.53B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $24.19 |
52-Week Low | $130.23 | $7.82 |
Enterprise Value | $88.12B | $2.28B |
Dividend Yield | 1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEM trades at $178.82, up 6.49% in the past 24 hours, reflecting strong momentum driven by record free cash flow and consistent earnings beats. The stock exhibits bullish technical signals with support at $177 and resistance at $181, while fundamentals show robust revenue growth to $11.91B in 2025 and a net income margin of 40.44%. Recent news highlights operational strength and gold price tailwinds.
Outlook remains positive with a consensus price target of $219.63, though risks include production costs and gold volatility. Analyst sentiment is strongly bullish with 21 buy ratings, supporting upside potential if execution continues.
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
